BSc (Hons), PhD

Position

Research Fellow, Centre for Paediatric Pharmacy Research

Tel: +44(0)20 7874 1535

Fax: +44(0)20 7387 5693

Email:

Areas of Expertise

Pharmacovigilance, Pharmacoepidemiology, Prescription-Event Monitoring, Paediatric pharmacovigilance, Use of medicines during pregnancy

Biography

Lynda Wilton obtained her undergraduate degree from the University of Exeter and her PhD from the University of Southampton. Whilst an undergraduate she worked at the Royal Naval Physiological Laboratory (UK), during the summer vacation. After completing her PhD she worked for several years in inhalation toxicology and during this time had a short sabbatical working with Professor Aviado at the University of Pennsylvania.

In 1980 she joined the Drug Safety Research Unit (DSRU) when it was founded and became its Principal Research Fellow. The major activity of the DSRU is monitoring the safety of recently marketed medicines prescribed in primary care, using the technique of Prescription-Event Monitoring (PEM). Lynda was involved in the setting up of this methodology and also in its ongoing development, including its use to monitor the outcomes of pregnancy and the use of newly marketed medicines in children.

Lynda is a member of the Editorial Board of the journal Drug Safety and also serves on the Elections Committee and the Education and Training Committee of the International Society of Pharmacovigilance. She has held honorary posts at the University of Southampton and the University of Portsmouth. Lynda also lectures on drug safety both in the UK and abroad, including Europe and India.

Research Interests

Lynda Wilton’s main research interests are the use of medicines in children, especially ‘off label’ use of newly marketed medicines and also the use of medicines by pregnant women. She also recognises the importance of good training of personnel working within drug safety and hence her involvement in the development of training courses in India with Symogen UK Ltd.

Selected publications

Kasliwal R, Wilton L, Shakir S. Safety Profile of Varenicline as used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study. Drug Safety 2009: issue 32:6 499-507

Vickova V, Cornelius V, Kasliwal R, Wilton L, Shakir S. Hypoglycaemia with anti-diabetic drugs: Results from Prescription-Event Monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug Safety 2009: issue 32:5 409-418

Barrera B, Wilton L, Shakir S. Use and risk management of Carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. Drug Safety 2009: issue 32:1 43-54

Perrio MJ, Wilton LV and Shakir SAW. A modified prescription-event monitoring study to assess the introduction of Flixotide EvohalerTM into general practice in England: an example of pharmacovigilance planning and risk monitoring. Pharmacoepidemiology and Drug Safety. 2007;16:969-978

Djulus J, Koren G, Einarson TR, Wilton L, Shakir S et al. Exposure to Mirtazapine During Pregnancy: A Prospective, Comparative Study of Birth Outcomes. Journal of Clinical Psychiatry. 2006;67:1280-1284

McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clinical Psychiatry. 2005;444-449

Pearce HM, Layton D, Wilton LV and Shakir SAW. Deep vein thrombosis and pulmonary embolism reported in the Prescription-Event Monitoring Study of Yasmin®. Brit J Clini Pharmacol. 2005:60:1:98-102

Wilton LV, Kollarova M, Heeley E and Shakir SA. Relative Risk of Vaginal Candidiasis After Use of Antibiotics Compared with Antidepressants in Women: Postmarketing Surveillance Data in England. Drug Safety. 2003;26(8):589-597

Wilton L and Shakir S. A Postmarketing Surveillance Study of Gabapentin as Add-on Therapy for 3,100 Patients in England. Epilepsia. 2002:43(9):983-992.

Heeley E, Wilton LV and Shakir SAW. Automated Signal Generation in Prescription-Event Monitoring. Drug Safety. 2002;25(6):423-32.

Biswas P, Wilton LV and Shakir SAW. Montelukast and improvement of eczema: observations from a prescription event monitoring study in England. Int J Clin Pharmacol Ther. 2001;39:529-33.

Wilton LV, Heeley EL, Pickering RM and Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacology. 2001;15(2):120-6

Wilton LV, Stephens MDB and Mann RD. Visual field defects associated with vigabatrin. BMJ. 1999;319:No 7218,1165-6.

Dunn N, Wilton LV, Shakir. Letter: Stevens-Johnson syndrome and antiepileptics. The Lancet. 1999:354;1033.

 

 

To top